Transenterix, inc. (TRXC)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Operating Activities
Net loss

-154,201

-61,777

-144,796

-119,980

-

-

-

-

Net loss

-

-

-

-

-46,948

-37,652

-28,358

-15,425

Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:
Goodwill and in-process research and development impairment

86,881

0

-

-

-

-

-

-

Depreciation

-

2,420

2,486

1,942

1,248

807

983

1,713

Amortization of intangible assets

10,301

10,868

7,858

6,967

2,185

503

500

-

Amortization of debt discount and debt issuance costs

1,513

725

510

177

142

83

103

-

Amortization of short-term investment discount

327

351

-

-

-

-

-52

-144

Amortization of debt issuance costs

-

-

-

-

-

-

-

39

Stock-based compensation

11,500

9,000

7,078

5,033

3,311

1,840

941

343

Inventory write-down related to restructuring

7,408

0

-

-

-

-

-

-

Non-employee warrant awards

-

-

838

-

-

-

-

-

Issuance of preferred stock warrants and debt issuance costs

-

-

-

-

-

-

-

128

Common stock issued for services

-

-

-

116

-

-

-

-

Inventory Write-down

1,523

0

-

2,565

-

-

-

-

Bad debt expense

1,600

0

-

-

-

-

-

-

Interest expense on deferred consideration - MST acquisition

756

0

-

-

-

-

-

-

Loss on disposal of property

-

-

-

-

-34

-86

-31

-48

Non-cash restructuring and other charges

-

-

-

2,556

-

-

-

-

Goodwill impairment

-

-

0

61,784

0

-

-

-

Impairment loss on property and equipment

-

-

-

-

-

-

450

0

Deferred tax benefit

-3,224

-3,377

-3,300

-5,562

-1,024

-

-

-

Loss on extinguishment of debt

-1,006

-1,400

-308

-

-

-

-

-

Fair Value Adjustment of Warrants

-2,200

14,300

83,734

-

-

-

1,800

0

Change in fair value of contingent consideration

9,600

1,000

-2,026

-482

400

-

-

-

Reversal of transfer fee accrual

0

2,994

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

-6,083

7,225

381

1,041

-133

-55

-402

226

Interest receivable

-26

-54

-23

6

5

-67

52

16

Inventories

16,404

2,145

2,981

6,647

4,630

-701

-731

143

Other current and long term assets

655

325

3,348

1,528

-728

170

328

108

Accounts payable

-668

767

-531

-356

1,096

-36

641

-

Accounts payable

-

-

-

-

-

-

-

-139

Accrued expenses

-1,180

2,134

2,093

1,112

5,371

363

868

-484

Deferred revenue

-959

825

1,088

-

-

-

-

-

Other long term liabilities

998

0

-

-

-

-

-

-

Net cash and cash equivalents used in operating activities

-73,484

-48,493

-47,295

-52,386

-

-

-

-

Investing Activities
Restricted cash

-

-

-

-

-

-

-

-125

Net cash and cash equivalents used in operating activities

-

-

-

-

-38,759

-33,353

-21,236

-14,148

Proceeds related to sale of assets, net

-

-

7,500

-

-

-

-

-

Purchase of short-term investments

12,883

55,439

-

-

-

-

-

-

Proceeds from maturities of short-term investments

65,000

4,000

-

-

-

-

-

-

Payment for acquisition of a business

0

5,800

-

-

25,000

-

-246

-

Payments for acquisition of a business

-

-

-

-

-

-

-

0

Purchase of property and equipment

437

770

1,566

1,361

1,234

2,174

1,377

184

Purchase of intellectual property

-

-

425

-

-

-

-

-

Purchase of investments

-

-

-

-

-

-

6,240

8,150

Proceeds from sale and maturities of investments

-

-

-

-

-

6,191

904

7,098

Proceeds from sale of property and equipment

0

32

-

-

-

25

-

49

Net cash and cash equivalents (used in) provided by investing activities

67,645

-53,481

5,509

-1,361

-

-

-

-

Financing Activities
Net cash and cash equivalents provided by (used in) investing activities

-

-

-

-

-26,234

4,042

-6,467

-1,187

Payment of notes payable

31,425

15,305

13,343

6,902

-

-

-

-

Proceeds from issuance of debt, net of debt discount

-

-

-

-

-

-

-

10,000

Payment of debt

-

-

-

-

-

2,877

1,519

0

Proceeds from issuance of debt and warrants, net of issuance costs

0

28,507

13,005

-

9,887

-

-

-

Payment of contingent consideration

0

770

7,181

1,182

-

-

-

-

Proceeds from issuance of common stock and warrants, net of issuance costs

25,777

279

77,579

58,029

58,331

-

-

-

Proceeds from issuance of common stock, net of issuance costs

-

-

-

-

-

52,433

-

-

Proceeds from issuance of debt, net of debt discount

-

-

-

-

-

4,291

1,998

-

Proceeds from issuance of preferred stock, net of issuance costs

-

-

-

-

-

-

28,199

268

Taxes paid related to net share settlement of vesting of restricted stock units

499

1,662

168

168

73

-

-

-

Proceeds from issuance of common stock related to sale of SurgiBot assets

0

3,000

-

-

-

-

-

-

Proceeds from exercise of stock options and warrants

538

12,403

34,479

166

-

-

-

-

Net (decrease) increase in cash, cash equivalents and restricted cash

-

-

-

-

-

24,627

-

-

Net cash and cash equivalents provided by (used in) financing activities

-5,609

26,452

104,371

49,943

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

364

-433

-

-

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-

-

431

-55

-

-

-

-

Net cash and cash equivalents provided by financing activities

-

-

-

-

68,404

53,938

28,821

10,227

Effect of exchange rate changes on cash and cash equivalents

-

-

-

-

22

-

-

-

Net increase in cash, cash equivalents and restricted cash

-11,084

-75,955

63,016

-3,859

3,433

-

-

-

Debt issuance costs

-

-

-

-

-

-

-

44

Proceeds from exercise of stock options and warrants

-

-

-

-

259

91

143

3

Net increase in cash and cash equivalents

-

-

-

-

-

-

1,118

-5,108

Supplemental Disclosure for Cash Flow Information
Interest paid

2,187

1,730

899

1,289

-

-

-

-

Interest paid

-

-

-

-

973

904

824

306

Supplemental Schedule of Non-cash Investing and Financing Activities
Transfer of inventories to property and equipment

486

2,160

1,258

3,198

-

-

-

-

Cashless exercise of warrants

0

4,272

149

-

-

-

-

-

Conversion of bridge notes to preferred stock

-

-

-

-

-

-

1,998

-

Conversion of bridge notes to preferred stock

-

-

-

-

-

-

-

0

Issuance of common stock warrants

-

-

-

-

97

54

1,909

0

Contingent consideration related to acquisition

-

-

-

-

23,900

-

-

-

Exchange of common stock for Series B Warrants

-

8,300

-

-

43,677

-

-

-

Transfer of property and equipment to inventories

323

637

-

-

-

-

-

-

Issuance of common stock as contingent consideration

-

-

5,227

-

-

-

-

-

Relative fair value of warrants issued with debt

-

-

300

-

97

-

-

-

Reclass of warrant liability to common stock and additional paid-in capital

0

23,774

78,359

-

-

-

-

-

Transfer of in-process research and development to intellectual property

-

-

17,913

-

-

-

-

-

Proceeds from sale of AutoLap assets exchanged for settlement of Company obligations

1,000

0

-

-

-

-

-

-

Deferred consideration - MST acquisition

0

5,962

-

-

-

-

-

-

Conversion of preferred stock to common stock

-

-

-

-

-

-

30,197

0

AutoLap
Gain Loss On Sale Of Developed System Assets Net

16,000

0

-

-

-

-

-

-

Proceeds related to sale of assets, net

15,965

0

-

-

-

-

-

-

SurgiBot System
Gain Loss On Sale Of Developed System Assets Net

-97

11,840

-

-

-

-

-

-

Inventory Write-down

1,500

0

-

-

-

-

-

-

Proceeds related to sale of assets, net

0

4,496

-

-

-

-

-

-